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Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbid-
ity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation
(HSCT). Progression to lower respiratory tract infection with clinical and radiological signs of pneumonia and
respiratory failure appears to depend on the intrinsic virulence of the specific CARV as well as factors specific to
the patient, the underlying disease, and its treatment. To better define the current state of knowledge of CARVs
in leukemia and HSCT patients, and to improve CARV diagnosis and management, a working group of the
Fourth European Conference on Infections in Leukaemia (ECIL-4) 2011 reviewed the literature on CARVs,
graded the available quality of evidence, and made recommendations according to the Infectious Diseases Society
of America grading system. Owing to differences in screening, clinical presentation, and therapy for influenza
and adenovirus, ECIL-4 recommendations are summarized for CARVs other than influenza and adenovirus.
Keywords. respiratory virus; transplantation; leukemia; bone marrow transplantation; hematopoietic.
Community-acquired respiratory virus (CARV) infec-
tions include a variety of RNA viruses such as human
orthymyxo-, paramyxo-, picorna-, and coronaviruses,
and DNA viruses such as adeno-, boca-, and polyomavi-
ruses [1, 2]. CARVs are detectable in the general
population throughout the year, but some CARVs show
a pronounced seasonality in temperate climates that can
exceed epidemic thresholds [1, 3]. CARV respiratory
tract infections (RTIs) range from asymptomatic replica-
tion to significant disease that typically affects the very
young and the very old populations, patients with
chronic medical conditions, and those with inherited,
acquired, or drug-induced immune dysfunction [1, 4].
In the past 2 decades, CARV RTIs have been recognized
as a significant cause of morbidity and mortality in pa-
tients with leukemia and those undergoing hematopoiet-
ic stem cell transplantation (HSCT) [5–9]. These
patients are at increased risk for progression to lower
RTI (LRTI) with clinical and radiological signs of pneu-
monia, respiratory failure, and fatal outcome. The risk
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of LRTI and fatal outcome appears to reflect the intrinsic viru-
lence of specific CARVs as well as factors specific to the patient,
the underlying disease, and its treatment.
To better define the impact of CARVs in leukemia and
HSCT patients, and to improve their diagnosis and manage-
ment, a working group of the Fourth European Conference on
Infections in Leukaemia (ECIL-4) 2011 reviewed the literature
on CARVs, graded the available evidence, and made recom-
mendations according to the Infectious Diseases Society of
America grading system (Supplementary Table 1). Because
several aspects regarding influenzavirus and adenovirus differ
substantially, including availability of vaccines and use of
specific antivirals, and screening of high-risk patients for
occurrence of gastrointestinal and disseminated disease, respec-
tively, ECIL recommendations are summarized for CARVs
other than influenza and adenovirus [10].
METHODS
PubMed was searched using each of the following terms: re-
spiratory virus, respiratory syncytial virus, metapneumovirus,
parainfluenza, rhinovirus, enterovirus, picornavirus, coronavi-
rus, polyomavirus, bocavirus; together with leukemia, or he-
matopoietic transplantation, or HSCT, or bone marrow
transplantation, or cord blood. Published studies were identi-
fied and reviewed in August 2011. In June 2012, 5 additional
papers and one paper in press were identified. The majority of
publications are retrospective observational studies, while few
prospective studies have been published dealing with this topic.
CARV Diagnostic Considerations
The diagnosis of CARV RTI is dependent on the specimen
and the laboratory assay(s) available. Potential specimens for
diagnostic testing include nasopharyngeal aspirates, nasopha-
ryngeal wash, swabs (preferably flocked for nasal sampling),
tracheal aspirates, and bronchoalveolar lavage (BAL) [1, 11].
Pooling bilateral nasopharyngeal with throat swabs is often
preferred over nasopharyngeal aspirates or nasopharyngeal
wash for upper RTI (URTI), and BAL is preferred over trache-
al aspirates for the diagnosis of LRTI. Laboratory tests include:
• Nucleic acid amplification testing (NAT), used as a generic
term to describe molecular genetic tests such as polymerase chain
reaction and others for the detection of viral DNA or RNA.
• Direct antigen detection (DAD), used as a generic term
to describe direct detection of antigens in a specimen using
specific antibodies in different assay formats (direct fluores-
cent antigen, enzyme-linked immunoassay, immune chroma-
tography, etc).
• Virus isolation by cell culture (VIC), used as a generic
term to describe cell culture for the isolation of infectious,
replicating viruses. VIC is performed using conventional and/
or shell vial cell culture techniques that can be combined with
DAD for agent identification.
VIC has a higher clinical specificity for disease but requires
a dedicated virology laboratory, is less sensitive than NAT, and
has a comparatively long turn-around time of 2–5 days. DAD
has a good clinical specificity, and a short turn-around time of
<4 hours, but has a lower sensitivity compared with VIC and
NAT [12–20]. NAT is often preferred because of a higher sen-
sitivity, an acceptable turn-around time of <24 hours, in addi-
tion to the potential of quantifying viral loads, multiplexing
with other infectious agents, detecting genetic variants, and
molecularly characterizing nosocomial outbreaks in special-
ized laboratories.
Definitions of CARV Infection and Disease
The detection of CARV in asymptomatic patients is increased
when using sensitive NAT [16, 21, 22]. As outlined elsewhere
previously [23], it is therefore important to distinguish between
patients with CARV infection and CARV infectious disease. To
provide a case definition comparable to one proposed by the Eu-
ropean Centre for Disease Prevention and Control for influenza
virus, the working group agreed to its adaptation for other
CARVs in leukemia and HSCT patients (Table 1).
• URTI was defined as the detection of CARVs above and
including the larynx (eg, in samples from nose, pharynx,
larynx, conjunctivae, or sinuses).
• URTI disease (URTID) was defined as the detection of
CARVs in upper respiratory tract fluid specimens together with
symptoms and/or signs and other causes excluded.
• LRTI was defined as the detection of CARVs below the
larynx (eg, in samples from trachea, bronchus, bronchoalveo-
lar sites).
• LRTI disease (LRTID) was defined as pathological sputum
production, hypoxia, or pulmonary infiltrates together with
identification of CARVs in respiratory secretions, preferentially
in samples taken from the sites of involvement (Table 1).
Characteristics of Specific CARVs
(Human) Respiratory Syncytial Virus
Repiratory syncytial virus (RSV) falls into 2 distinct antigenic
subgroups, A and B. Infections occur year-round but peak
during the cold season, with increases in URTID (eg, sinusitis,
rhinitis, and laryngitis) in young children, and LRTID (eg,
bronchiolitis and pneumonia) in neonates [3, 24]. RSV RTI of
patients with HSCT and/or other hematological diseases
follow the community activity and reflect an increased risk of
community-acquired, household, and nosocomial transmis-
sion [15, 25–27]. In the past, the standard diagnostic assays
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have been DAD and VIC, but these techniques have been re-
placed or complemented by NAT in many centers [14, 28].
RSV infections occur in 0.3%–2.2% of pediatric patients with
acute myeloid leukemia [29] and in 1%–12% of adult patients
with hematological malignancy and HSCT [8, 30–36]. Infec-
tion in the first 100 days after myeloablative allogeneic HSCT
has been associated with an increased risk of persistent air
flow decline at 1 year after transplant [37]. Progression to
LRTID is observed in 38% (mean; range, 0%–68%) of leuke-
mia and HSCT patients, with an average mortality of 32%
(range, 0%–70%), as reviewed elsewhere [14, 38]. Risk factors
for LRTID include infection during preengraftment, lympho-
penia, older age, allogeneic HSCT, and severe immunodefi-
ciency due to a range of contributing factors (Table 2).
Although the risk of a poor clinical outcome progressively in-
creases with overall falling absolute lymphocyte counts [9],
varying thresholds of lymphopenia have been reported in clin-
ical studies (0.3 to 0.1 × 109/L) [8, 31, 32, 39]. Rapid diagnos-
tics, infection control measures, and deferral of chemotherapy
and/or HSCT are important considerations [22]. Corticoste-
roid treatment is a risk factor in leukemia patients [30], but
the role of corticosteroids is controversial, since improving re-
spiratory function has been seen despite increasing RSV loads
and prolonged shedding [40, 41]. Currently, there is only
limited evidence for effective treatments because of the lack of
potent antiviral drugs and sufficiently powered, randomized
controlled clinical trials (RCTs) [42, 43]. However, pooling of
published studies suggests that treating URTID in HSCT and
leukemia at risk for LRTID and treating manifest LRTID with
ribavirin and intravenous immunoglobulin (IVIG) improves
outcome [14, 33, 38]. It should be recognized that proper
meta-analyses were not possible, and the results should there-
fore be interpreted with caution.
Human Parainfluenza Virus
The human parainfluenza virus (HPIV) species -1, -2, -3, and
-4 cause mild URTID throughout the year, but type-specific
seasonal increases of URTID and LRTID with laryngotrachei-
tis, bronchiolitis, and pneumonia are seen in 15% of infected
children during autumn and spring [3, 44]. Diagnosis of HPIV
infection has been largely made using DAD or VIC covering
HPIV-1, -2, and -3, but is increasingly replaced by NAT also
identifying HPIV-4. In adult and pediatric leukemia and
HSCT patients, symptomatic HPIV infections have been re-
ported to range from 2% to 7%, of which at least one-third are
manifest as LRTID [9, 32, 45–49]. Among the pediatric pa-
tients, 90% of HPIV infections were deemed to be communi-
ty-acquired. Given an estimated incubation period of 2.6 days
(95% confidence interval [CI], 2.1–3.1) [50] and a high rate of
17.9% asymptomatic shedding [36], outpatient and nosocomi-
al outbreaks are not infrequent, indicating the need for infec-
tion control strategies [18, 46–48, 51–56]. In HSCT recipients
with URTID and LRTID, HPIV-3 is the most commonly
Table 2. Risk Factors of Respiratory Syncytial Virus–Associated
Complications in Hematopoietic Stem Cell Transplantation
Patients
Progression to LRTID
• Lymphopenia <0.2 × 109/L
• Older age
• Mismatched/unrelated donor
• Allogeneic HSCT <1 mo
• Neutropenia <500/µL
• No therapy with aerosolized ribavirin + IVIG
Mortality
• Preengraftment
• Lymphopenia <0.2 × 109/L
• Allogeneic HSCT <1 mo
• Severe immunodeficiency
• Older age (>65 y)
Abbreviations: HSCT, hematopoietic stem cell transplantation; IVIG,
intravenous immunoglobulin; LRTID, lower respiratory tract infectious disease.
Table 1. Definitions of Community-Acquired Respiratory Virus
Respiratory Tract Infectious Disease
Case Classification
• Possible case: meeting the clinical criteria of RTID
• Probable case: meeting the clinical criteria of RTID together
with an epidemiological link
• Confirmed case: meeting the clinical criteria of RTID and the
laboratory criteria
Clinical criteria
• New onset of symptoms AND at least 1 of the following 4
respiratory symptoms:
○ Cough
○ Sore throat
○ Shortness of breath
○ Coryza
• AND the clinician’s judgment that the illness is due to an
infection
Epidemiological criteria
• An epidemiological link to human-to-human transmission
(activity in the community, contact with visitor, another patient,
or healthcare worker)
Laboratory criteria
• Detection of CARV in a clinical specimen, preferably from the
site of clinical involvement, by at least 1 of the following:
○ Virus isolation by cell culture
○ Direct virus antigen detection
○ Nucleic acid amplification testing
• AND exclusion of a major role of other etiologies
Abbreviations: CARV, community-acquired respiratory virus; RTID, respiratory
tract infectious disease.
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detected type in children as well as in leukemia and HSCT
patients (80%–90%) followed by HPIV-1 and -2 [44, 45, 57,
58]. Nonmyeloablative conditioning has been associated with
HPIV URTI after 30 days after transplant [48]. URTI has been
associated with significant airflow decline in 40% of patients
[37], which may progress to LRTID in 13%–37% and a fatal
outcome in 10%–30% [45, 57]. Reported risk factors for
LRTID are higher corticosteroid exposure, neutropenia, lym-
phopenia, infection early after allogeneic HSCT, a higher
APACHE II score, and coinfections [32, 45, 47, 48, 57–60].
Treatment options are limited by the lack of effective agents
and RCTs, although some centers consider treating HPIV
URTID in patients with risk factors for LRTID and HPIV
LRTID, with ribavirin and/or IVIG [8, 18, 31, 36, 37, 48, 61–
64]. Bronchiolitis obliterans syndrome and obstructive airflow
decline have been associated with HPIV infection within the
first 3 months after allogeneic HSCT, which persisted at 1 year
after transplant [37, 65].
Human Metapneumovirus
Human metapneumovirus (HMPV) is a paramyxovirus
closely related to RSV, causing increases in URTID and tra-
cheobronchitis in 5%–20% of children and adults during
winter. HMPV infection is commonly diagnosed by NAT, and
rates range from 2.5% to 9% during the first 2 years after allo-
geneic HSCT [32, 66–68]. Asymptomatic and prolonged shed-
ding has been reported in HSCT patients [36, 69, 70]. HPMV
URTID in HSCT patients can present with flu-like symptoms
[66, 67]. In HSCT patients with pneumonia, HMPV is fre-
quently codetected with other pathogens, including bacteria,
fungi, and other CARVs, as well as cytomegalovirus, all which
obscure the attributable morbidity [32, 66]. Recipient cytomeg-
alovirus seropositivity was a risk factor in one study of HSCT
patients [36]. Single cases of severe disease and fatal outcome
have been reported [71, 72]. No general recommendation for
treatment can currently be made, although some centers con-
sider treating HMPV LRTID with ribavirin and/or IVIG
despite the lack of supporting studies [19, 26, 32, 66, 67].
Human Coronavirus
Human coronaviruses (HCoVs) circulate throughout the year
with a slight predominance in winter, presumably causing
10%–30% of cases of the “common cold.” HCoVs are divided
into group 1–like (CoV-229E and -NL63) and group 2–like
(CoV-OC43 and -HKU1) agents that are molecularly distinct.
Although VIC and DAD are available, most centers use NAT
in multiplex formats, reporting rates of 5.7% among acutely
symptomatic patients. The incubation period has been esti-
mated as 3.2 days (95% CI, 2.8–3.7) [50] followed by a median
detectability of 2–3 weeks. URTID with rhinitis, pharyngitis,
and laryngitis is the most common manifestation. Cases of
LRTID with bronchitis, bronchiolitis, and pneumonia have
been reported in very young (age <1 year) and/or in immuno-
deficient patients [73–75]. In HSCT patients, HCoV has been
detected in 6.7%–15.4%, but asymptomatic shedding may be
as high as 41% [21]. In symptomatic HSCT patients, coinfec-
tions with other pathogens are frequent. LRTID and pneumonia
with fatal outcome occur rarely [76]. General recommenda-
tions for treatment are limited in view of the largely benign
course, the lack of effective antiviral agents, and appropriate
clinical studies [21, 75, 77, 78].
Human Rhinovirus
Human rhinoviruses (HRhVs) belong to the Picornaviridae
family and are divided into 3 species called A, B, and C en-
compassing >100 serotypes. HRhVs circulate throughout the
year and are the most common cause of URTID (rhinorrhea,
postnasal drip, cough) and occasionally (tracheo-)bronchitis
[1]. The incubation period has been estimated as 1.9 days
(95% CI, 1.4–2.4) [50]. Diagnosis largely depends on NAT, al-
though DAD for rapid testing and VIC are performed in spe-
cialized laboratories. In allogeneic HSCT recipients, HRhVs
have been identified as the most frequent CARVs, reaching a
cumulative incidence as high as 22.3% by day 100 [21], with
detection rates of up to 40% among symptomatic HSCT pa-
tients [34]. HRhV infection may be asymptomatic in 13% of
HSCT patients, and prolonged shedding over 4 weeks is fre-
quent, with coinfections with other CARVs occurring in 19%
of patients [79]. One study reports that higher HRhV loads
correlate with symptomatic presentations [80]. LRTID with
frank pneumonia is rare and may occur in <10% of allogeneic
HSCT infected with HRhV, usually in myeloablative condi-
tioning, with an estimated mortality of <10% [32, 59, 79, 81].
The role of HRhV treatment is limited by the lack of agents
and clinical trials.
Other CARVs
Human enteroviruses (HEnV), encompassing at least 66 sero-
types, also belong to the Picornaviridae family. HEnVs are de-
tected in <5% of hematological patients with URTID, which
may progress to LRTID in 13% [9, 34, 79]. Although some
HEnVs are identifiable by VIC, current laboratory diagnosis
relies mostly on NAT, which may also be designed to detect
other picornaviruses such as HRhV or parechoviruses. Lym-
phopenia of <500/µL is a risk factor for LRTID in HSCT
patients.
Human bocavirus (HBoV) and human polyomavirus
(HPyV) infections have been detected in patients with hema-
tological malignancies or HSCT [82]. However, studies of
cases with a well-documented clinical course and proven
disease by histopathology are missing. Accordingly, risk
factors for disease and the need for therapy are not well
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defined. HBoV belongs to the Parvoviridae family and is de-
tected in 5% of children with RTI. HBoV has been frequently
codetected with other viral agents, preventing an unequivocal
attribution to URTID or LRTID. In BAL from adult patients,
HBoV was detected in 0%–3% of cases. Recent studies suggest
that HBoV loads >5 log10 copies/mL in respiratory fluids are
more likely to indicate clinically significant replication [83].
Disseminated HBoV infection has been reported, but the clin-
ical interpretation of NAT signals, even when found in blood
or organ sites, may be difficult, since its prolonged persistence
has been described akin to parvovirus B19 [84].
HPyV RTIs include KIPyV and WUPyV, which have been
detected in 0.2% and 1.4% of children with acute URTID, re-
spectively [85]. KIPyV has been detected more frequently in re-
spiratory fluids of HSCT patients (17%) compared with other
patients (5%) [86]. In symptomatic children with leukemia or
HSCT, higher viral loads in BAL have been reported [87]. In a
large prospective study of 222 HSCT patients, KIPyV and
WUPyV showed a cumulative incidence of 26% and 8%, respec-
tively, after 1 year, with no seasonal pattern, but an increased
rate in patients <20 years of age (hazard ratio, 4.4 and 4.6,
respectively) [88]. Sputum production and wheezing were
associated with KIPyV or WUPyV detection, but not with graft-
vs-host disease, cytomegalovirus reactivation, neutropenia,
lymphopenia, hospitalization, or death [88]. Pending further
studies, routine testing for KIPyV and WUPyV cannot be rec-
ommended, and there are currently no data supporting the
treatment of KIPyV or WUPyV LRTID [86].
ECIL-4 Recommendations on Prevention of CARV Infection
The working group recognizes that the person-to-person
transmission of CARVs should lead to measures for their pre-
vention through infection control measures (Table 3). These
recommendations should be implemented at the level of pa-
tients, relatives, and healthcare workers, both inside and
outside of medical institutions (Table 3).
Administration of IVIG preparations to HSCT and leukemia
patients with hypogammaglobulinemia <4 g/L may reduce the
risk of morbidity or mortality secondary to CARV RTIDs
(CIII). During RSV outbreaks in the community indicating an
increased risk of exposure, the use of intravenous monoclonal
antibody specific for the RSV-F protein (palivizumab) may be
considered for pediatric patients aged <2 years as monthly pro-
phylaxis (CIII), but it is not indicated in other patient groups.
ECIL-4 Recommendations for Diagnosis of CARV Infection
To balance costs and clinical benefit, screening all patients for
CARVs is currently not indicated unless indicated in the
context of an infection control investigation of nosocomial
transmission and prevention, and thus laboratory testing
should focus on symptomatic patients (Table 4). Taking into
account the clinical impact of CARVs in HSCT and leukemia
patients and the differences among centers in the technical
and financial resources for comprehensive CARV diagnostics
by multiplex NAT, the working group recommends prioritiz-
ing laboratory tests for specific CARVs such as influenza, RSV,
and HPIV (Table 4).
ECIL-4 Treatment Recommendations for CARV Infection
Reflecting the clinical impact compared to other CARVs, the
working group distinguishes the need of treatment for influen-
za A and B [10], RSV and HPIV, taking into account the
higher risk for poor outcome in specific patient groups. The
treatment of RSV and HPIV may involve the deferral of con-
ditioning therapy, treatment with aerosolized ribavirin, or off-
label use of systemic ribavirin, whereas no general recommen-
dations for other CARVs can be made at this time (Table 5).
The corresponding modalities of RSV therapy and systemic
ribavirin are summarized in Tables 6 and 7, respectively. The
working group is cautious about the use of intravenous mono-
clonal antibody specific for the RSV-F protein, because exist-
ing data outside of single case reports do not support its
beneficial effect and the cost is very high. Therefore, only very
young (age <2 years) allogeneic HSCT patients with LRTID or
at high risk for progression to RSV LRTID might be consid-
ered for treatment with intravenous monoclonal antibody spe-
cific for the RSV-F protein (eg, palivizumab 15 mg/kg body
weight) (CIII; Supplementary Table 1), while this drug should
not be considered in other patient groups.
Table 3. Recommendations on Prevention of Community-
Acquired Respiratory Virus Infection
• It is recommended that patients and contact persons should
adhere to good personal hygiene, including frequent hand
washing, covering the mouth when coughing and sneezing, and
disposing safely of oral and nasal secretions (AII).
• Leukemia patients and HSCT patients should avoid contact with
individuals with RTI in the hospital and in the community (AII).
• Young children should be restricted from visiting patients and
wards because of the higher risk of CARV exposure, prolonged
shedding, and ease of transmission (BII).
• All visitors and HCWs with RTI should be restricted from access
to patients and wards (AII).
• Inside care facilities, infection control measures should be
applied to leukemia and HSCT patients with RTI, including
isolation rooms and application of strict protection measures
(gloves, gowning, masks, eye protection) for HCWs and visitors
(AII).
• Outpatients with RTI should be seen and treated in accordance
with infection control measures, ie, in facilities and rooms
separated from other HSCT and leukemia patients (AII).
See Supplementary Table 1 for the Infectious Diseases Society of America
grading system.
Abbreviations: CARV, community-acquired respiratory virus; HCW, healthcare
worker; HSCT, hematopoietic stem cell transplantation; RTI, respiratory tract
infection.
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Withholding treatment for RSV infection might be consid-
ered for selected stable leukemia and HSCT patients after
careful evaluation of risk factors for morbidity and mortality
and the possibility of appropriate follow-up visits considering,
for example, remission of underlying disease, absence of im-
munosuppressive drug treatment, absence of the risk factors
associated with LRTID, or mortality (CIII). Although some
centers would treat patients with HPIV URTID and risk
factors listed in Table 3, treatment of HPIV URTID is not
generally recommended given the clinically undefined risk
and benefit ratio (CIII).
Overall, the evidence is more limited for patients with au-
tologous HSCT and/or hemato-oncological disease.
Infection control measures should be applied to patients
undergoing autologous HSCT or chemotherapy for hemato-
oncological diseases with CARV URTID or LRTID (BIII).
Deferral of conditioning/chemotherapy should be considered
for patients with CARV-RTID scheduled for autologous HSCT
or chemotherapy for hemato-oncological diseases (BIII). Treat-
ment of CARV RTID other than influenza is not generally rec-
ommended for patients undergoing autologous HSCT or
chemotherapy for hemato-oncological diseases (CIII).
DISCUSSION AND OUTLOOK
The working group acknowledges that despite the growing
awareness of infections by CARVs in HSCT and leukemia pa-
tients, well-designed studies are largely lacking that evaluate
diagnostic and therapeutic strategies for CARV. On the diag-
nostic level, studies are needed to identify the most appropriate
diagnostic test and specimen from the upper and lower respira-
tory tracts. The detection of CARVs in peripheral blood has
been associated with significant LRTID, disseminated disease,
and poor outcome, but requires evaluation by specifically
Table 6. Recommendations for Respiratory Syncytial Virus
Treatment in Hematological Patients
• For treatment of RSV, aerosolized ribavirin can be administered
as 2 g for 2 h every 8 h or as 6 g over 18 h/d for 7–10 d (BII).
• For treatments using aerosolized ribavirin, appropriate
precautions should be applied to avoid environmental exposure
and thereby potentially teratogenic effects in pregnant
healthcare workers and visitors (AII).
• Patients on aerosolized ribavirin should be monitored and treated
for adverse events including claustrophobia, bronchospasm,
nausea, conjunctivitis, and declining pulmonary function (BII).
• For treatment of RSV, systemic ribavirin can be administered
orally (BIII) or intravenously for patients unable to take oral
medication (10–30 mg/kg body weight in 3 divided doses) (CIII).
• Patients on systemic ribavirin should be monitored and treated
for adverse events including hemolysis, abnormal liver function
tests, and declining renal function (BIII).
• For allogeneic HSCT patients with RSV LRTID or at high risk for
RSV LRTID, aerosolized or systemic ribavirin therapy may be
combined with IVIG or anti-RSV-enriched antibody preparations
(BIII).
See Supplementary Table 1 for the Infectious Diseases Society of America
grading system.
Abbreviations: HSCT, hematopoietic stem cell transplantation; IVIG,
intravenous immunoglobulin; LRTID, lower respiratory tract infectious
disease; RSV, respiratory syncytial virus.
Table 4. Recommendations for Diagnosis of Community-
Acquired Respiratory Virus Infection
• HSCT candidates or HSCT recipients with URTID or LRTID
should be tested for CARVs to guide infection control measures,
treatment, and decisions regarding deferral of chemotherapy or
HSCT (AII).
• Specimens should preferably be taken from the site of clinical
involvement, preferably pooled swabs for URTID, or BAL for
LRTID, (or tracheal aspirate if BAL is not available) (BII).
• First-line diagnostic testing should be performed for influenza A
and B, RSV, and HPIV (AII).
• Testing for other CARVsa should be considered according to risk
of exposure and the local epidemiology, or if testing for the first-
line CARVs is negative (BIII).
• Patients with LRTID should be considered for BAL and broader
diagnostic testing including lung biopsy as clinically indicated
(BII).
See Supplementary Table 1 for the Infectious Diseases Society of America
grading system.
Abbreviations: BAL, bronchoalveolar lavage; CARV, community-acquired
respiratory virus; HPIV, human parainfluenza virus; HSCT, hematopoietic stem
cell transplantation; LRTID, lower respiratory tract infectious disease; RSV,
respiratory syncytial virus; URTID, upper respiratory tract infectious disease.
a Including human enterovirus, human metapneumovirus, human rhinovirus,
human coronavirus, and human adenovirus.
Table 5. Recommendations for Community-Acquired Respiratory
Virus Treatment in Hematopoietic Stem Cell Transplantation and
Leukemia Patients
• Deferral of conditioning therapy should be considered for
patients with CARV RTID planned for allogeneic HSCT (BII )
• Deferral of conditioning/chemotherapy could be considered for
patients with CARV RTID scheduled for chemotherapy of
hemato-oncological diseases (BIII )
• Patients with RSV URTID undergoing allogeneic HSCT or
recipients of allogeneic HSCT with risk factors for progression
to RSV LRTID and death should be treated with aerosolized or
systemic ribavirin and IVIG (BII )
• For allogeneic HSCT patients with HPIV LRTID, treatment with
aerosolized or systemic ribavirin and IVIG may be considered
(BIII )
• For allogeneic HSCT patients with CARV URTID or CARV
LRTID other than RSV or HPIV, aerosolized or systemic
ribavirin and IVIG treatment cannot be recommended (CIII )
See Supplementary Table 1 for the Infectious Diseases Society of America
grading system.
Abbreviations: CARV, community-acquired respiratory virus; HPIV, human
parainfluenza virus; HSCT, hematopoietic stem cell transplantation; IVIG,
intravenous immunoglobulin; LRTID, lower respiratory tract infectious
disease; RSV, respiratory syncytial virus; RTID, respiratory tract infectious
disease; URTID, upper respiratory tract infectious disease.
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designed studies. There is interest to identify and confirm risk
factors of severe disease and poor outcome and to evaluate labo-
ratory markers of virus-specific immunity as surrogate markers
of disease and recovery. The recent attempts to use RSV loads
as a virological surrogate marker of antiviral treatment by small
interfering RNA and/or clinical outcome may have a pacemaker
role for other CARVs [89]. Importantly, the currently available
treatments for CARV URTID and LRTID lack rigorous evalua-
tion in appropriately sized, prospective randomized controlled
trials. This is needed for comparing aerosolized ribavirin with
systemic (oral) ribavirin; for evaluating the role of expensive
IVIG preparations in combination with ribavirin; and for deter-
mining the use of intravenous monoclonal antibody specific for
the RSV-F protein (palivizumab, motavizumab) as postexposure
prophylaxis for high-risk patients as well as therapy for RSV
URTID and LRTID. The development of vaccines is seen as an
important area of research. Finally, a better understanding of
the indirect alloimmune pathology of CARVs on clinical
outcome is important [65], but also depends on a better defini-
tion of the direct viral impact.
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